Lambers Heerspink HJ - Search Results

1

Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.

Kohan DE, Lambers Heerspink HJ, Coll B, Andress D, Brennan JJ, Kitzman DW, Correa-Rotter R, Makino H, Perkovic V, Hou FF, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D. Kohan DE, et al. Among authors: lambers heerspink hj. Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1568-74. doi: 10.2215/CJN.00570115. Epub 2015 Jul 7. Clin J Am Soc Nephrol. 2015. PMID: 26153128 Free PMC article. Clinical Trial.

2

Update on microalbuminuria as a biomarker in renal and cardiovascular disease.

Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D. Lambers Heerspink HJ, et al. Curr Opin Nephrol Hypertens. 2006 Nov;15(6):631-6. doi: 10.1097/01.mnh.0000247496.54882.3f. Curr Opin Nephrol Hypertens. 2006. PMID: 17053479 Review.

3

Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system.

Lambers Heerspink HJ, Witte EC, Bakker SJ, de Jong PE, de Zeeuw D, Gansevoort RT. Lambers Heerspink HJ, et al. Kidney Int. 2008 Aug;74(3):377-83. doi: 10.1038/ki.2008.186. Epub 2008 May 14. Kidney Int. 2008. PMID: 18480748 Free article.

4

Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality.

Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT; PREVEND Study Group. Lambers Heerspink HJ, et al. Am J Epidemiol. 2008 Oct 15;168(8):897-905. doi: 10.1093/aje/kwn209. Epub 2008 Sep 5. Am J Epidemiol. 2008. PMID: 18775924

5

First morning voids are more reliable than spot urine samples to assess microalbuminuria.

Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R. Witte EC, et al. Among authors: lambers heerspink hj. J Am Soc Nephrol. 2009 Feb;20(2):436-43. doi: 10.1681/ASN.2008030292. Epub 2008 Dec 17. J Am Soc Nephrol. 2009. PMID: 19092125 Free PMC article.

6

Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?

de Zeeuw D, Lambers-Heerspink H. de Zeeuw D, et al. J Am Soc Nephrol. 2009 Apr;20(4):688-9. doi: 10.1681/ASN.2009020172. Epub 2009 Mar 11. J Am Soc Nephrol. 2009. PMID: 19279124 No abstract available.

7

The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.

Lambers Heerspink HJ, Agarwal R, Coyne DW, Parving HH, Ritz E, Remuzzi G, Audhya P, Amdahl MJ, Andress DL, de Zeeuw D. Lambers Heerspink HJ, et al. Am J Nephrol. 2009;30(3):280-6. doi: 10.1159/000225903. Epub 2009 Jun 15. Am J Nephrol. 2009. PMID: 19521070 Clinical Trial.

8

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.

Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Lambers Heerspink HJ, et al. J Hypertens. 2009 Dec;27(12):2321-31. doi: 10.1097/HJH.0b013e3283310f92. J Hypertens. 2009. PMID: 19727007 Review.

9

Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?

Lambers Heerspink HJ, de Zeeuw D. Lambers Heerspink HJ, et al. Am J Nephrol. 2010;31(5):458-61; discussion 468. doi: 10.1159/000292501. Epub 2010 Apr 22. Am J Nephrol. 2010. PMID: 20413960 Free article. No abstract available.

10

Dual RAS therapy not on target, but fully alive.

Lambers Heerspink HJ, de Zeeuw D. Lambers Heerspink HJ, et al. Nephron Clin Pract. 2010;116(2):c137-42. doi: 10.1159/000315882. Epub 2010 Jun 1. Nephron Clin Pract. 2010. PMID: 20516713 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page